Lung Cancer
We recommend
Sotorasib v léčbě pacientů s NSCLC s mutací G12C onkogenu KRAS – zkušenosti z reálné české praxe
Skutečně prakticky uchopili přednášející sympozium společnosti Amgen na XXIX. jihočeských onkologických dnech, které proběhly v dubnu 2024. MUDr. Gabriela Krákorová, Ph.D., z Kliniky pneumologie a ftizeologie LF UK a FN Plzeň na třech kazuistikách svých pacientů s metastatickým nemalobuněčným karcinomem plic (NSCLC) s mutací KRASG12C po selhání předchozí léčby ukázala, že v běžné praxi můžeme očekávat efekt a snášenlivost sotorasibu odpovídající výsledkům klinické studie CodeBreak 100. Zdůraznila také, že u NSCLC nejde o vzácnou mutaci –…
Excellent effect of sotorasib in a higher line of treatment in a patient with NSCLC with G12C mutation of KRAS – a case study
We present a case study of an elderly patient with non-small cell lung cancer (NSCLC) treated with…
Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC)…
Articles on this topic
Inhibition of Mutated KRAS Protein as a New Option for Targeted Treatment of Non-Small Cell Lung Cancer
RAS proteins are molecular switches for several intracellular signaling pathways. Their…
Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the…
Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation.…
Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell…
Subscribe
Most read on this topic
- Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
- Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
- Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
- Inhibition of Mutated KRAS Protein as a New Option for Targeted Treatment of Non-Small Cell Lung Cancer
- Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
- Excellent effect of sotorasib in a higher line of treatment in a patient with NSCLC with G12C mutation of KRAS – a case study
Journal on this topic
Related topic